...
首页> 外文期刊>Brain research >α-Synuclein mRNA and soluble α-synuclein protein levels in post-mortem brain from patients with Parkinson's disease, dementia with Lewy bodies, and Alzheimer's disease
【24h】

α-Synuclein mRNA and soluble α-synuclein protein levels in post-mortem brain from patients with Parkinson's disease, dementia with Lewy bodies, and Alzheimer's disease

机译:帕金森氏病,路易体痴呆和阿尔茨海默氏病患者验尸后脑中α-突触核蛋白mRNA和可溶性α-突触核蛋白蛋白水平

获取原文
获取原文并翻译 | 示例
           

摘要

α-Synuclein is a neuronal protein implicated in the etiology of Parkinson's disease (PD) and dementia with Lewy bodies (DLB). Whilst increased α-synuclein expression due to gene duplication or triplication can cause familial PD, previous studies of α-synuclein levels in idiopathic disease have produced conflicting data. We quantified α-synuclein mRNA and soluble protein in five human post-mortem brain regions from four groups of individuals with PD, DLB, Alzheimer's disease (AD) and matched controls. α-Synuclein mRNA levels, measured using quantitative real-time PCR, did not differ significantly between groups in any brain regions examined. In contrast, levels of soluble α-synuclein protein, measured by ELISA, were significantly lower in 4 of the 5 regions for patients with DLB, and in 2 of the 5 regions for patients with PD, compared to controls. Soluble α-synuclein protein levels were not significantly different in the AD patients, compared to controls, in 4 of the 5 regions. This study indicates that although levels of soluble α-synuclein protein are lower in DLB and PD, there is no evidence for a corresponding decrease in α-synuclein mRNA levels. This might result from altered translation, or removal of α-synuclein protein from a soluble detectable state, either by turnover or conversion to an insoluble form.
机译:α-突触核蛋白是一种神经元蛋白,与帕金森氏病(PD)和路易体痴呆(DLB)的病因有关。尽管由于基因重复或三重复引起的α-突触核蛋白表达增加可导致家族性PD,但先前对特发性疾病中α-突触核蛋白水平的研究产生了矛盾的数据。我们从PD,DLB,阿尔茨海默氏病(AD)和相匹配的对照组的四个人的五个人类死后大脑区域中量化了α-突触核蛋白mRNA和可溶性蛋白。使用定量实时PCR测量的α-突触核蛋白mRNA水平在所检查的任何大脑区域中的组之间没有显着差异。相比之下,与对照组相比,通过ELISA测定的DLB患者5个区域中的4个区域和PD患者5个区域中的2个区域中通过ELISA测定的可溶性α-突触核蛋白水平显着降低。与对照组相比,AD患者在5个区域中的4个区域中可溶性α-突触核蛋白蛋白水平没有显着差异。这项研究表明,尽管DLB和PD中的可溶性α-突触核蛋白蛋白水平较低,但没有证据表明α-突触核蛋白mRNA水平相应降低。这可能是由于翻译改变或通过转换或转化为不溶形式而将α-突触核蛋白从可溶性可检测状态中去除所致。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号